| Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141) |
|---|
| 09/30/2004 | US20040191840 Using immunoglobulins to inactivate viricidal and antitumor activities of huma n type interferon for preventing autoimmunity and graft rejection; immunosuppressants |
| 09/30/2004 | US20040191826 Dipeptidyl peptidases |
| 09/30/2004 | US20040191767 Comprises nucleotide sequences coding hepatitis core protein fusion for generating vaccine to prevent infcetion and treat liver dysfunction; gene therapy and cell-mediated immune response |
| 09/30/2004 | US20040191756 Transgenic rodent for diagnosing and identifying modulator for treatment and prevention inflammatory disorders |
| 09/30/2004 | US20040191304 Vaccine adjuvant properties of lipsomes formed at elevated temperatures from the polar chloroform extractable lipids from mycobacterium bovis bacillus calmette-guerin |
| 09/30/2004 | US20040191272 Methods and reagents for vaccination which generate a CD8 T cell immune response |
| 09/30/2004 | US20040191270 Vaccine compositions |
| 09/30/2004 | US20040191268 Isolated, synthetic or recombinant nonapeptide of a minor Histocompatability antigen HA-1 comprising the sequence valine-leucine-X-aspartic acid-aspartic acid-leucine-leucine-glutamic acid-alanine wherein X is arginine or histidine; bone marrow transplants; graft versus host disease; leukemia |
| 09/30/2004 | US20040191242 Method for producing a vaccine |
| 09/30/2004 | US20040191239 Treatment and prevention of reactive oxygen metabolite-mediated cellular damage |
| 09/30/2004 | US20040191236 Administering antigen associated with disease, a dendritic cell binding agent specific for the antigen, and an autologous dendritic cell; immunotherapy |
| 09/30/2004 | US20040191235 Method for obtaining antigen-specific tr1 regulatory lymphocytes |
| 09/30/2004 | US20040191234 Administering prebiotic such as fructo-oligosaccharide; measles prevention; vaccines; nutrients |
| 09/30/2004 | US20040191228 Methods of kidney transplantation utilizing developing nephric tissue |
| 09/30/2004 | US20040191219 HSA-free formulations of interferon-beta |
| 09/30/2004 | US20040191216 Medicines including interferon and administering system thereof |
| 09/30/2004 | US20040191214 Nucleoside vaccine adjuvants |
| 09/30/2004 | US20040191185 Ephedrine or fenfluramine; aluminum foil coated with a thin layer of drug is heated to form vapor; which condenses to form aerosol; rapid peak plasma concentration |
| 09/30/2004 | US20040191184 Delivery of muscle relaxants through an inhalation route |
| 09/30/2004 | US20040191183 Delivery of antiemetics through an inhalation route |
| 09/30/2004 | US20040191182 Delivery of analgesics through an inhalation route |
| 09/30/2004 | US20040191181 Vaporization of diphenhydramine from solid for breathing administerig |
| 09/30/2004 | US20040191180 Breathing analgesics after vaporization for administering pain killer for headaches |
| 09/30/2004 | US20040191179 Breathing antidepressants from aerosols for administering bupropion by heating on a solid support |
| 09/30/2004 | CA2633287A1 Combinations of rapamycin or its derivatives and pimecrolimus for the treatment of inflammation- and immunologically-mediated diseases |
| 09/30/2004 | CA2519084A1 Methods for inducing the differentiation of monocytes into functional dendritic cells and immunotherapeutic compositions including such dendritic cells |
| 09/30/2004 | CA2518728A1 Cathepsin s inhibitors |
| 09/30/2004 | CA2518371A1 Antibodies against human il-21 receptor and uses therefor |
| 09/30/2004 | CA2518227A1 Water-soluble phenylpyridazine derivative and medicine containing the same |
| 09/30/2004 | CA2517671A1 Combinations of rapamycin or its derivatives and pimecrolimus for the treatment of inflammation- and immunologically-mediated diseases |
| 09/29/2004 | EP1462449A1 Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha levels |
| 09/29/2004 | EP1462114A1 Methods and means to suppress symptons of an allergic disease by inhibiting the glucocorticoid-induced tumor necrosis factor receptor (GRIT or TNFRSF18) |
| 09/29/2004 | EP1462108A1 Interferon g (g) production promoter |
| 09/29/2004 | EP1461614A2 Functional inactivation of cxcr4-mediated responses in growth hormone transgenic mice through socs3 upregulation |
| 09/29/2004 | EP1461443A2 Carbohydrate-associated proteins |
| 09/29/2004 | EP1461436A1 Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers |
| 09/29/2004 | EP1461418A2 Methods for the production of 3-o-deactivated-4'-monophosphoryl lipid a (3d-mla) |
| 09/29/2004 | EP1461358A1 Ifnar2 muteins, their production and use |
| 09/29/2004 | EP1461347A1 2-o-(-d-glucopyranosyl)ascorbic acid, process for its production, and foods and cosmetics containing compositions comprising it |
| 09/29/2004 | EP1461334A2 Pyrazole derived kinase inhibitors |
| 09/29/2004 | EP1461333A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
| 09/29/2004 | EP1461327A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
| 09/29/2004 | EP1461326A1 Benzothiazole- and benzoxazole-4,7-dione derivatives and their use as cdc25 phosphatase inhibitors |
| 09/29/2004 | EP1461325A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
| 09/29/2004 | EP1461321A1 3,4-di-substituted pyridazinediones as cxc chemokine receptor antagonists |
| 09/29/2004 | EP1461316A2 Synthesis of 2-cyanoziridine-1-carboxamide |
| 09/29/2004 | EP1461306A1 Quaternary ammonium compounds and their use as antimuscarinic agents |
| 09/29/2004 | EP1461122A2 Treatment of genitourinary tract disorders |
| 09/29/2004 | EP1461092A1 Process for coating a surface of a stent |
| 09/29/2004 | EP1461086A2 Enzymatic cleavable reagents for specific delivery to disease sites |
| 09/29/2004 | EP1461081A2 Anti-cd45rb antibodies for use in treating autoimmune disease and transplant rejection |
| 09/29/2004 | EP1461074A2 Agents for enhancing the immune response |
| 09/29/2004 | EP1461062A2 Composition and method for treating chronic allograft rejection |
| 09/29/2004 | EP1461054A2 Gram positive bacteria preparations for the treatment of diseases comprising an immune dysregulation |
| 09/29/2004 | EP1461050A1 Oral immunostimulation of mammals, birds, and reptiles from (1-4) linked beta-d-mannuronic acid |
| 09/29/2004 | EP1461038A1 Arylsulfonamide derivatives for use as ccr3 antagonists in the treatment of inflammatory and immunological disorders |
| 09/29/2004 | EP1461031A2 Formulations for oral administration of cromolyn sodium |
| 09/29/2004 | EP1461027A1 Treatment of neoplasia |
| 09/29/2004 | EP1461015A2 Compositions containing both sedative and non-sedative antihistamines |
| 09/29/2004 | EP1460964A2 Oral immunostimulation of mammals, birds, fish and reptiles from (1-4) linked b -d-mannuronic acid |
| 09/29/2004 | EP1299350B1 Substituted benzamides for immune enhancement and for the treatment of cancer, infection and manic-depressive illness |
| 09/29/2004 | EP1276493B1 Cxcr4 agonist treatment of hematopoietic cells |
| 09/29/2004 | EP1210320B1 Aminobenzophenones as inhibitors of il-1beta and tnf-alpha |
| 09/29/2004 | EP1202959B1 Aminobenzophenones as inhibitors of il-1-beta and tnf-alpha |
| 09/29/2004 | EP1202957B1 Aminobenzophenones as inhibitors of il-1beta and tnf-alpha |
| 09/29/2004 | EP1200400B1 Substituted pyrrolidin-2,3,4-trion derivatives useful as nmda-receptor antagonists |
| 09/29/2004 | EP1189881B1 Propanoic acid derivatives that inhibit the binding of integrins to their receptors |
| 09/29/2004 | EP1181278B1 Cyclic amine derivatives and their uses |
| 09/29/2004 | EP1169302B1 N-(2-phenyl-4-amino-butyl)-1-naphthamides as neurokinin-1 receptor antagonists |
| 09/29/2004 | EP1144412B1 Immunosuppressive effects of pteridine derivatives |
| 09/29/2004 | EP1123295B1 Bicyclic nitrogen heterocycles |
| 09/29/2004 | EP1100483B1 Glucocorticoid-selective anti-inflammatory agents |
| 09/29/2004 | EP1059913B1 Emulsion preconcentrates containing cyclosporin or a macrolide |
| 09/29/2004 | EP1019040B1 Aryl ureas for the treatment of inflammatory or immunomodulatory diseases |
| 09/29/2004 | EP1015012A4 Peptide inhibitors of nuclear protein translocation having nuclear localization sequences and methods of use thereof |
| 09/29/2004 | EP1003503B1 Therapeutic combinations comprising amlodipin and atorvastatin |
| 09/29/2004 | EP0993439B1 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as mek inhibitors |
| 09/29/2004 | EP0989999B1 Antitumoral composition based on immunogenic polypeptide with modified cell location |
| 09/29/2004 | EP0983080B1 Synthetic, statistic thymus peptide combination and its use as a preparation with immunological and/or endocrinological effect |
| 09/29/2004 | EP0914417B1 Human dnase ii |
| 09/29/2004 | EP0826006B1 Transepithelial transport of molecular species |
| 09/29/2004 | EP0804238B1 Method to prevent transplant rejection |
| 09/29/2004 | CN1533442A Cimeric immunomodulatory compounds and methods of using the same |
| 09/29/2004 | CN1533399A 免疫调节肽 Immunomodulatory peptides |
| 09/29/2004 | CN1533392A Pyrazolopgrimidinone derivatives having PED 7 inhibitory activity |
| 09/29/2004 | CN1533391A Tricyclic compounds and their uses |
| 09/29/2004 | CN1533388A Substituted piperazine compounds and their use as fatty acid oxidation inhibitors |
| 09/29/2004 | CN1533387A 1-phenysulfonyl-1,3-dihydro-2H-indole-2-one derivatives, their preparation and their therapeutic use |
| 09/29/2004 | CN1533374A Substitutled cyclohexane-1,4-diamine derivatives |
| 09/29/2004 | CN1533285A Adjuvant combination formulations |
| 09/29/2004 | CN1533284A Use of biologically active HIV-1 Tat, fragments or derivatives thereof for preventing or therapeutic vaccination and/or treating other diseases |
| 09/29/2004 | CN1533279A Organo-phosphorous compounds for activating gamma/delta T-cells |
| 09/29/2004 | CN1533242A Foot and mouth disease virus vaccine |
| 09/29/2004 | CN1531967A Use of mometasone furoate for treating airway nassage and lung diseases |
| 09/29/2004 | CN1531935A Reforced multiple state defensive system for multi-path interactive controllable disease prevention and disease treatment |
| 09/29/2004 | CN1531925A Process for preparing colatemo solid preparation and its solid preparation |
| 09/29/2004 | CN1168735C New lipid esters of nucleoside monophosphates and their use as immunosuppressive drugs |
| 09/29/2004 | CN1168733C Novel prodrugs for therapy of tumors and inflammatory disorders |
| 09/29/2004 | CN1168726C Novel vitamin D analogues |
| 09/29/2004 | CN1168725C Formulation for protection against oxidative stress containing beozofuranone derivatives |